SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of October 2019

Commission File Number 001-37410

ESSA Pharma Inc.

(Translation of registrant’s name into English)

Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 
 

EXPLANATORY NOTE

 

The following exhibits included herein were filed by the Registrant with the Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval on the dates noted below:

 

Exhibit  
   
99.1 Material Change Report dated October 21, 2019

 

Exhibit 99.1 of this Report on Form 6-K shall be incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-222654, File No. 333-225969 and File No. 333-234136) and Form S-8 (File No. 333-225056) under the Securities Act of 1933, as amended.

 

EXHIBITS INCLUDED AS PART OF THIS REPORT

   
Exhibit  
   
99.1 Material Change Report dated October 21, 2019

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

             
   

ESSA PHARMA INC.

    (Registrant)
     
Date: October 21, 2019   By:  

/S/ DAVID WOOD

   

Name:

Title:

 

David Wood

Chief Financial Officer

 

Exhibit 99.1

 

 

 

FORM 51-102F3

MATERIAL CHANGE REPORT

 

Item 1: Name and Address of Company
   
  ESSA Pharma Inc. (“ESSA” or the “Company”)
  Suite 720, 999 West Broadway
  Vancouver, British Columbia, Canada V5Z 1K5
Item 2: Date of Material Change
  October 17, 2019
Item 3: News Release
  A news release announcing the material change referred to in this report was issued on October 18, 2019 through Canada NewsWire and a copy has been filed on SEDAR at www.sedar.com.
Item 4: Summary of Material Change
  On October 18, 2019, ESSA announced that Ari Brettman has been appointed to the board of the directors of the Company (the “Board”) pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announced that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments.
Item 5: Full Description of Material Change
  5.1 Full Description of Material Change
  On October 18, 2019, ESSA announced that Ari Brettman has been appointed to the Board pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences. The Company also announced that Otello Stampacchia, who has represented Omega Funds, has resigned from the Board as he focuses on new investments.
  David R. Parkinson, President and Chief Executive Officer, said, “We are extremely appreciative of Otello’s support as a member of the Board of Directors. Ari’s perspectives will be valuable as we execute on the path towards a successful IND filing of EPI-7386.”
  Dr. Brettman is currently a Principal in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Dr. Brettman joined Clarus in September 2014. Dr. Brettman is currently a member of the Board of Directors of Praxis Precision Medicines and Anthos Therapeutics as well as an Observer on the Board of Directors of Talaris Therapeutics.
  Dr. Brettman completed a residency in internal medicine and a fellowship in cardiology at Massachusetts General Hospital (“MGH”) and was also a National Institutes of Health-sponsored post-doctoral fellow at the MGH Center for Systems Biology. He received his M.D. from Duke University and his A.B. in History and Science from Harvard College. While a medical student, he was a Sarnoff Cardiovascular Research Foundation Fellow at Stanford University, where he studied angiogenesis.

 

 
 

 

 

  5.2 Disclosure of Restructuring Transactions
  Not applicable.
Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102
  Not applicable.
Item 7: Omitted Information
  Not applicable.
Item 8: Executive Officer
  For further information, please contact David Wood, Chief Financial Officer of the Company at 778-331-0962.
Item 9: Date of Report
  October 21, 2019

 

 

 

 

 

2